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Although Hyper-IgE Syndrome (HIES) is a rare immunodeficiency disorder, presenting symptoms may be as common as lung
and skin infections. Symptoms are usually nonspecific such as recurrent abscesses, folliculitis, and pneumonias along with skeletal
abnormalities. Careful history of susceptibility to skin and lung infections, thorough family history, and findings on physical exam
can guide towards the diagnosis of this often-eluded condition. Early optimization of therapy with prophylactic antibiotics can
prevent recurrent infections and future complications and improve quality of life and longevity of survival. We present a case of a
young female with Hyper-IgE Syndrome with a novel mutation in STAT 3 gene who initially presented with long standing history
of intractable skin abscesses being managed as Hidradenitis Suppurativa.

1. Background
Hyper-IgE syndrome (HIES), also commonly known as Job’s
syndrome, was first described by Davis et al. in 1966 as
a syndrome associated with severe dermatitis with “cold”
abscesses [1, 2]. Subsequently, this was further characterized
by typical facial appearance with high levels of immunoglobulin E (IgE) by Buckley et al. in 1972 [3]. Since then, additional
features of HIES have been recognized and it has since been
regarded as a multisystem disorder characterized by chronic
eczema, recurrent staphylococcal skin and lungs infections,
pneumatocele formation, candidiasis, retained primary teeth,
joint hyperextensibility, low bone density with bone fractures,
scoliosis, and craniosynostosis [4, 5].
It is a rare immunological disorder with an estimated
incidence of 1 in 500,000 to 100,000 individuals [4, 6] with
both autosomal dominant (AD) and recessive forms (AR)
of inheritance [1, 7]. Mutation in the signal transduction
and activation of transcription 3 gene (STAT3) with gainof-function is the most prevalent mutation described and
accounts for majority of its autosomal dominant and sporadic
forms [1, 5, 7]. Tyrosine kinase 2 (TYK2) and dedicator of
cytokinesis 8 (DOCK8) genes mutations are implicated in
recessive forms [7, 8]. Unlike AD-HIES, they have higher

predisposition to viral infections, severe atopic eczema, food
allergy, neurologic symptoms, and malignancies. [9]
National Institute of Health (NIH) clinical HIES scoring
system was developed in 1999 based on 19 clinical and
laboratory findings [4]. This gave an estimate of likelihood of
HIES diagnosis with more than 40 points suggestive of the
diagnosis [4, 8]. Genetic study for mutation analysis is the
mainstay of diagnosis confirmation. Among the STAT3 gene
mutations in literature for AD-HIES, V463E variant of STAT3
gene with a “loss of function” (located at the DNA-binding
domain), found in our patient, has neither been published as
a pathogenic nor been a benign variant to our knowledge. The
variant was not observed in large population cohorts [10].

2. Case Presentation
A 21-year-old white female was referred to our AllergyImmunology Clinic for a history of multiple intractable
cutaneous abscesses and cysts for several years. She had
undergone multiple incision and drainage and had been
treated with antibiotics as well as topical and systemic steroids
intermittently with minimal relief and developed methicillin resistant staphylococcal aureus (MRSA) colonization
during the same period. She was at the time clinically
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diagnosed as Hidradenitis Suppurativa. Her medical history
was significant for hypertension, diabetes mellitus type II,
hyperlipidemia, obesity, and anxiety.
On further questioning, she reported more than fifteen hospitalizations for pneumonias. According to her
mother, she had recurrent pneumonias, upper respiratory
tract infections, sinusitis, mastoiditis, and oral candidiasis
since early childhood. The patient denied any history of
atopic dermatitis, other types of eczema, or food allergy.
Evaluation for cystic fibrosis and hypogammaglobulinemia
at the time had been negative. More recently, she had
been admitted for septic shock secondary to septic arthritis
of left hip. She also had multiple fractures with minimal
trauma since childhood and was clinically diagnosed with
osteogenesis imperfecta. She also reported history of primary
teeth retention for which she had underwent orthodontic
surgery at the age of 12 years. She had a normal birth history
with normal documented developmental milestones and
was up-to-date with her immunizations. She had Penicillin
and Trimethoprim-Sulfamethoxazole (TMP-SMX) listed as
allergy after she developed rash with their use when she was
a toddler.
Family history was pertinent for her paternal grandmother with recurrent pneumonias, who passed away at
40 years of age secondary to a severe lung infection. Her
biological brother had a history of recurrent skin boils.
Important physical findings included coarse facial feature
with exacerbated pore size, deep set eyes, broad nasal bridge,
high arched palate, and multiple scattered healed scars
on skin with some remnant cold abscesses. She had mild
thoracic scoliosis. Pulmonary and cardiovascular exam were
unremarkable.
Laboratory investigations revealed a normal complete
blood count with no eosinophilia. IgE level was elevated
at 5,842 IU/ml, with erythrocyte sedimentation rate of
64 mm/hr and C-reactive protein of 1.56 mg/dl. IgG, IgM,
and IgA levels were within normal limit. Tetanus and
pneumonia titers were normal. Total complement (CH50)
levels were normal and testing for chronic granulomatous
disease was unrevealing. Due to history, physical findings,
and these initial labs, we suspected Hyper-IgE Syndrome. A
calculated HIES score was 63 (>40 required for diagnosis).
With a high suspicion of AD-HIES, mutation analysis of
STAT3 gene was sent which detected a novel pathogenic
mutation, C.1388 T>A (pVal463Glu) at DNA-binding domain
of STAT3 gene. Although this mutation in STAT3 gene
has never been published as a pathogenic mutation leading
to AD-HIES, missense variants in nearby residues have
been reported in association to those reported in the
Human Gene Mutation Database in association with HIES
[11].
Penicillin allergy testing and TMP-SMX oral challenge
were performed in the clinic. With a normal response,
she was started on TMP-SMX (800mg-160mg) once daily
prophylactically for prevention of infections (MRSA sensitive
to TMP-SMX).
Patient was advised to follow up for clinical response and
monitoring tolerance to treatment. She was asked to have
regular dental exam, chest imaging, bone density scan, and
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Figure 1: Facial characteristic of AD-HIES patient: coarse facial
feature with exacerbated pore size, deep set eyes, and broad nasal
bridge.

pulmonary function test screening. She was also advised to
have genetic counselling. Genetic testing for her biological
brother was offered.

3. Discussion
Mutations in STAT3 gene account for majority of autosomal
and sporadic HIES [1, 5, 7]. Located in human chromosome
17q21, STAT3 plays a vital role in signal transduction induced
by many cytokines (IL-6, IL-10, IL-17, IL-21, IL-22) [4, 12].
Its mutation yields abnormal inflammatory response leading
to immunological abnormalities and higher predisposition
to infections [4]. Our patient had pathogenic mutation of
V463E, a nonconservative amino acid substitution. This
variant is located within the DNA-binding domain, and
missense variants in nearby residues have been reported
[11]. Pathogenic variants described to date include missense,
single amino acid in-frame deletions, and splice variants, all
being “gain-of-function” related mutations. Several hotspot
variants in SH2 and DNA-binding domain are known with
four recurrent variants occurring at CpG dinucleotides:
c.1144C>T, c.1145G>A, c.1268G>A, and c.1909G>A as well as
a recurrent three-base in-frame deletion c.1387 1389delGTG
[13].
This entity is a rare disease without any known prevalence
and does not have any preference for sex or race [3]. The disease severity also does not correlate with the individual’s IgE
level. [14] The criteria of HIES or Grimbacher scale provide
insight into times of diagnostic dilemma (Figure 3); however,
definitive test relies on genetic and molecular analysis [1, 8].
In the case described, high index of suspicion was made
due to presence of cutaneous abscesses (Figure 2), colonization with MRSA, high level of IgE, recurrent pneumonia,
history of retained primary teeth, multiple fractures with
minimal trauma, scoliosis, and typical facial characteristics
(Figure 1).
Long-term antibiotic therapy with antistaphylococcal
activity (e.g., TMP-SMX, Penicillin, Cephalosporins) can
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Figure 2: Scattered healed scars on skin with some remnant cold abscesses.

Figure 3: Hyper-IgE Syndrome/Grimbacher scale: our patient score highlighted (total score: 63).

contribute to significant reduction in skin and lung infections
such that risk of developing serious future infections, pneumatoceles, and lung damage outweighs the risk of developing
antibiotic resistance [4, 8, 15]. Among immunomodulatory
agents, subcutaneous Interferon-gamma (0.05mg/m2 three
times weekly) has been shown to decrease IgE levels and
infection susceptibility; however, no randomized control
trials exist [13]. Recently, a monoclonal anti-IgE, omalizumab has been shown to help decline serum IgE with
improvement in atopic conditions; however, in Hyper-IgE
state, this benefit is unknown and an area of further study
[13, 15].

4. Learning Objectives
(i) Identification of Hyper-IgE Syndrome in patients
with characteristic history and clinical features can
assist in early diagnosis and help initiate preventive
measures for future infections and complications.
(ii) Clinical features can determine the type of HIES;
confirmatory test is genetic testing and molecular
analysis.
(iii) HIES can be a sporadic or hereditary disorder. V463E
variant of STAT3 gene, located at the DNA-binding
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domain with loss of function mutation, is a novel
mutation seen in our patient that could be associated
with this disease entity.
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